What is the projected market valuation for the mRNA Therapeutics Contract Development and Manufacturing Organization Market in 2035?

The projected market valuation for 2035 is approximately 7.998 USD Billion. Read More

What are the primary segments of the mRNA Therapeutics Contract Development and Manufacturing Organization Market?

The primary segments include Type of Service, Application, End User, and Therapeutic Area. Read More

How much is the Development Services segment projected to grow by 2035?

The Development Services segment is projected to grow from 0.76 USD Billion in 2024 to 2.4 USD Billion by 2035. Read More

What is the projected market size for the Manufacturing Services segment by 2035?

The Manufacturing Services segment is expected to reach approximately 3.84 USD Billion by 2035. Read More

Which application area is expected to have the highest market valuation by 2035?

Vaccines are projected to have the highest market valuation, growing from 1.01 USD Billion in 2024 to 3.25 USD Billion by 2035. Read More

What is the anticipated growth for the Oncology application segment by 2035?

The Oncology application segment is expected to grow from 0.76 USD Billion in 2024 to 2.45 USD Billion by 2035. Read More

Which end user segment is projected to dominate the market by 2035?

Pharmaceutical Companies are projected to dominate the market, growing from 1.2 USD Billion in 2024 to 3.8 USD Billion by 2035. Read More

mRNA Therapeutics Contract Development Manufacturing Organization Market

Q: What was the market valuation for the mRNA Therapeutics Contract Development and Manufacturing Organization Market in 2024?

The overall market valuation was 2.53 USD Billion in 2024. Read More

Q: What is the expected CAGR for the mRNA Therapeutics Contract Development and Manufacturing Organization Market from 2025 to 2035?

The expected CAGR during the forecast period 2025 - 2035 is 11.03%. Read More

Q: Which companies are considered key players in the mRNA Therapeutics Contract Development and Manufacturing Organization Market?

Key players include Moderna, BioNTech, CureVac, Translate Bio, Ginkgo Bioworks, Arcturus Therapeutics, eTheRNA, GenScript, and Sutro Biopharma. Read More

ID: MRFR/LS/40582-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

MRNA Therapeutics Contract Development and Manufacturing Organization Market Research Report By Type of Service (Development Services, Manufacturing Services, Laboratory Services), By Application (Vaccines, Oncology, Genetic Disorders, Viral Infections), By End User (Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations), By Therapeutic Area (Infectious Diseases, Cancer Immunotherapy, Autoimmune Diseases) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

mRNA Therapeutics Contract Development Manufacturing Organization Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)11.03%

2024 Market Size$ 2.53 Billion

2025 Market Size$ 2.81 Billion

2035 Market Size$ 8 Billion

Key Players

Moderna

BioNTech

CureVac

Translate Bio

Ginkgo Bioworks

Arcturus Therapeutics

Trends

Increased Collaboration
Investment Surge
Regulatory Adaptation

Opportunities

Expansion of Biopharmaceutical Sector
Regulatory Support for mRNA Innovations
Rising Demand for Personalized Medicine

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type of Service (USD Billion)
  1. 4.1.1 Development Services
  2. 4.1.2 Manufacturing Services
  3. 4.1.3 Laboratory Services
2. 4.2 Healthcare, BY Application (USD Billion)
  1. 4.2.1 Vaccines
  2. 4.2.2 Oncology
  3. 4.2.3 Genetic Disorders
  4. 4.2.4 Viral Infections
3. 4.3 Healthcare, BY End User (USD Billion)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Biotechnology Companies
  3. 4.3.3 Academic Institutions
  4. 4.3.4 Research Organizations
4. 4.4 Healthcare, BY Therapeutic Area (USD Billion)
  1. 4.4.1 Infectious Diseases
  2. 4.4.2 Cancer Immunotherapy
  3. 4.4.3 Autoimmune Diseases
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Moderna (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 BioNTech (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 CureVac (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Translate Bio (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ginkgo Bioworks (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Arcturus Therapeutics (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 eTheRNA (BE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GenScript (CN)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sutro Biopharma (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE OF SERVICE
4. 6.4 US MARKET ANALYSIS BY APPLICATION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 US MARKET ANALYSIS BY THERAPEUTIC AREA
7. 6.7 CANADA MARKET ANALYSIS BY TYPE OF SERVICE
8. 6.8 CANADA MARKET ANALYSIS BY APPLICATION
9. 6.9 CANADA MARKET ANALYSIS BY END USER
10. 6.10 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF SERVICE
13. 6.13 GERMANY MARKET ANALYSIS BY APPLICATION
14. 6.14 GERMANY MARKET ANALYSIS BY END USER
15. 6.15 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
16. 6.16 UK MARKET ANALYSIS BY TYPE OF SERVICE
17. 6.17 UK MARKET ANALYSIS BY APPLICATION
18. 6.18 UK MARKET ANALYSIS BY END USER
19. 6.19 UK MARKET ANALYSIS BY THERAPEUTIC AREA
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF SERVICE
21. 6.21 FRANCE MARKET ANALYSIS BY APPLICATION
22. 6.22 FRANCE MARKET ANALYSIS BY END USER
23. 6.23 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF SERVICE
25. 6.25 RUSSIA MARKET ANALYSIS BY APPLICATION
26. 6.26 RUSSIA MARKET ANALYSIS BY END USER
27. 6.27 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA
28. 6.28 ITALY MARKET ANALYSIS BY TYPE OF SERVICE
29. 6.29 ITALY MARKET ANALYSIS BY APPLICATION
30. 6.30 ITALY MARKET ANALYSIS BY END USER
31. 6.31 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF SERVICE
33. 6.33 SPAIN MARKET ANALYSIS BY APPLICATION
34. 6.34 SPAIN MARKET ANALYSIS BY END USER
35. 6.35 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF SERVICE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE OF SERVICE
42. 6.42 CHINA MARKET ANALYSIS BY APPLICATION
43. 6.43 CHINA MARKET ANALYSIS BY END USER
44. 6.44 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
45. 6.45 INDIA MARKET ANALYSIS BY TYPE OF SERVICE
46. 6.46 INDIA MARKET ANALYSIS BY APPLICATION
47. 6.47 INDIA MARKET ANALYSIS BY END USER
48. 6.48 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF SERVICE
50. 6.50 JAPAN MARKET ANALYSIS BY APPLICATION
51. 6.51 JAPAN MARKET ANALYSIS BY END USER
52. 6.52 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF SERVICE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF SERVICE
58. 6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION
59. 6.59 MALAYSIA MARKET ANALYSIS BY END USER
60. 6.60 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF SERVICE
62. 6.62 THAILAND MARKET ANALYSIS BY APPLICATION
63. 6.63 THAILAND MARKET ANALYSIS BY END USER
64. 6.64 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF SERVICE
66. 6.66 INDONESIA MARKET ANALYSIS BY APPLICATION
67. 6.67 INDONESIA MARKET ANALYSIS BY END USER
68. 6.68 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF SERVICE
70. 6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION
71. 6.71 REST OF APAC MARKET ANALYSIS BY END USER
72. 6.72 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF SERVICE
75. 6.75 BRAZIL MARKET ANALYSIS BY APPLICATION
76. 6.76 BRAZIL MARKET ANALYSIS BY END USER
77. 6.77 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF SERVICE
79. 6.79 MEXICO MARKET ANALYSIS BY APPLICATION
80. 6.80 MEXICO MARKET ANALYSIS BY END USER
81. 6.81 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF SERVICE
83. 6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION
84. 6.84 ARGENTINA MARKET ANALYSIS BY END USER
85. 6.85 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF SERVICE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF SERVICE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF SERVICE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF SERVICE
100. 6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION
101. 6.101 REST OF MEA MARKET ANALYSIS BY END USER
102. 6.102 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE OF SERVICE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE OF SERVICE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.3.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.4.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.5.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.6.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.7.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.8.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.9.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.10.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.11.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.12.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.13.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.14.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.15.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.16.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.17.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.18.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.19.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.20.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.21.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.22.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.23.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.24.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.25.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.26.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.27.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.28.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.29.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE OF SERVICE, 2025-2035 (USD Billion)
  2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.30.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

mRNA Therapeutics Contract Development Manufacturing Organization Market Segmentation

mRNA Therapeutics Contract Development Manufacturing Organization Market By Type of Service (USD Billion, 2025-2035)

Development Services
Manufacturing Services
Laboratory Services

mRNA Therapeutics Contract Development Manufacturing Organization Market By Application (USD Billion, 2025-2035)

Vaccines
Oncology
Genetic Disorders
Viral Infections

mRNA Therapeutics Contract Development Manufacturing Organization Market By End User (USD Billion, 2025-2035)

Pharmaceutical Companies
Biotechnology Companies
Academic Institutions
Research Organizations

mRNA Therapeutics Contract Development Manufacturing Organization Market By Therapeutic Area (USD Billion, 2025-2035)

Infectious Diseases
Cancer Immunotherapy
Autoimmune Diseases

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035